Stay updated on CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Sign up to get notified when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.

Latest updates to the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded 'Gastric cancer' under Conditions and introduced a new Resources link to the Genetic and Rare Diseases Information Center. Removed the older Revision: v3.4.1 entry.SummaryDifference0.2%

- Check18 days agoChange DetectedThe revision label updated from v3.4.0 to v3.4.1. This appears to be a version update with no impact on the study details or page content.SummaryDifference0.0%

- Check32 days agoChange DetectedAnticoagulation guidance updated to allow therapeutic LMWH under specified conditions and eligibility/safety criteria revised across GI cancer cohorts; baseline requirements and related notes were updated.SummaryDifference1%

- Check39 days agoChange DetectedThe page revision updated from v3.3.3 to v3.3.4. No visible changes to study details, eligibility criteria, or other core content.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded a dedicated Locations section listing Kansas and Pennsylvania sites and updated the page to revision v3.3.3.SummaryDifference0.3%

- Check90 days agoChange DetectedThe page revision from v3.2.0 to v3.3.2 did not change the study details or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab
Enter your email address, and we'll notify you when there's something new on the CAMILLA Clinical Trial: Cabozantinib + Durvalumab ± Tremelimumab page.